Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01701583 · ClinicalTrials.gov registry record · Phase 4
Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria
A Phase 4 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT01701583: Completed Phase 4 study, sponsored by University of Colorado, Denver.
NCT01701583 is a Phase 4 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 10 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01701583, a Phase 4 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study looks at changes in cell proteins in people with chronic hives treated with omalizumab.
Primary Outcome
In patients with chronic urticaria who respond clinically to omalizumab, the proteome of blood basophils will be measured at baseline (pre-treatment) and at weeks 6 and 13 (post-treatment). The number of participants with a change observed in basophil proteome out of the total number of participants, stratified by responders and non-responders, is reported.
Interventions
- DRUG Omalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-04 |
| Est. Completion | 2017-10 |
| Phase | Phase 4 |
What the finished NCT01701583 record still lists
NCT01701583 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Omalizumab is the first listed.
NCT01701583 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01701583 about?
NCT01701583 is a clinical study titled "Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria". This study looks at changes in cell proteins in people with chronic hives treated with omalizumab.
What is the current status of trial NCT01701583?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2013-04. Estimated completion is 2017-10.
What interventions are being tested in trial NCT01701583?
The interventions under investigation include: Omalizumab (DRUG).
Who is sponsoring clinical trial NCT01701583?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01701583's enrollment target sits among peer trials
10 1940th of 2000 higher than 33 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia